Clinical value of flash glucose monitoring in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion.
You are not Logged in
• A 24-week retrospective cohort study in CSII-treated type 1 diabetes patients exposed(1:1) to the flash glucose monitoring system vs. self-monitoring of capillary bloodglucose (SMBG).
• The primary outcome was the difference in haemoglobin A1c (HbA1c) levels betweenboth groups at the end of the study.
• Thirty-six patients with a mean age of 38.2 years (range 22–55 years) and a mean type 1diabetes duration of 20.9±7.8 years, treated with CSII for 7.1±5.4 years, were enrolled.
• At the end of the study, mean HbA1c levels improved in patients in the flash glucosemonitoring group (7.1±0.7 vs. 7.8±1.0; p=0.04).
• The flash group showed a significant decrease in HbA1c levels of -0.4% (95% CI: -0.6, -0.2; p=0.004) during follow-up, whereas SMBG patients did not show a significantbenefit (-0.1%; 95% CI: -0.3, 0.4; p=0.64).
• Flash glucose monitoring patients captured 93.9% of data through 17.8±9.9 scans daily.
• The flash glucose monitoring cohort showed a three-fold increase in daily self-monitoring of glucose, while daily frequency of self-monitoring of blood glucosedecreased during the study (-1.8 tests/24 hours [95% CI: -3, -0.7; p=0.01]).
• No safety issues related to flash glucose monitoring were recorded.